Effect of supplementation in treatment of polycystic ovary syndrome

Effects of zinc supplementation on nitric oxide and biomarkers of oxidative stress in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201407115623N24

Enrollment

Registered

2014-11-09

Start date

2014-05-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention group: Zinc tablet, 50 mg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo tablet, daily, for 8 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women aged 18-40 years Patients with PCOS according to Rotterdam criteria

Exclusion criteria

Exclusion criteria: Hyperprolactinemia Thyroid disorders Liver or kidney diseases Pregnancy and lactation The use of medications such as insulin sensitizers, insulin, and diuretics. Subjects following a special diet or consuming drugs with an effect on hormonal profile like oral conceptives (OCP), steroid hormones, or any other drugs probably to affect ovarian action in the last 3 months T2DM

Design outcomes

Primary

Measure	Time frame
Free testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Dehydroepiandrosterone (DHEA). Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Clinical observation.;Alopecia. Timepoint: Baseline and End-of-trial. Method of measurement: Clinical observation.	—

Secondary

Measure	Time frame
17-OH progesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

17-OH progesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026